Skip to content
GERICLINICS

GeriQBank · Paper IV · Q1

Management of ST-Elevation Myocardial Infarction and Recent Advances

High YieldAsked ×215-mark essay
Chapter
Cardiology
Years asked
Not recorded in the source
Frequency
Set 2× in Paper IV (2009–2025)

As set in the university papers — 2 wordings

  • Discuss the management of ST elevation myocardial infarction. What are the recent advances in the approach to this entity?

    Paper IV · Cardiovascular Medicine · asked ×1 · 15-mark essay · see in paper list

  • What are the types of acute coronary syndromes? How are they diagnosed, investigated and treated based on the latest recommendations published in literature — both acutely and on outpatient follow-up?

    Paper IV · Cardiovascular Medicine · asked ×1 · 15-mark essay · see in paper list

Answer framework

  1. Definition and diagnosis — type 1 MI; three diagnostic elements; atypical presentation in older people
  2. Reperfusion — total ischaemic time; time targets; primary PCI versus fibrinolysis; the pharmaco-invasive pathway; TRIANA
  3. Adjunctive drugs — DAPT and anticoagulation; prasugrel and ticagrelor in older people; statin, beta-blocker, ACE inhibitor; PPI; heparin dosing
  4. Procedural and elderly-specific points — radial access; bleeding; CABG; ICD; CGA, not age; cardiac rehabilitation
  5. Recent updates — 2025 ACC/AHA ACS guideline; complete revascularisation; potent P2Y12 inhibitors; DAPT de-escalation; 2023 ESC; shock; lipids

An exam answer plan drawn from the detailed answer below. Use it to attempt the question first.

Detailed answer

Pro · free in beta
Attempt it firstOutline your answer as a 15-mark essay before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer

Short revision answer

  • STEMI is a type 1 MI: complete thrombotic coronary occlusion after plaque rupture or erosion. Diagnosis = clinical presentation + ST elevation + a rise in high-sensitivity troponin.
  • Older people often present atypically — dyspnoea, confusion, lethargy, epigastric, shoulder or back pain — and only a minority have typical chest pain, so keep a high index of suspicion.
  • Total ischaemic time determines salvage; benefit is greatest within 2–3 hours. Targets: first medical contact to diagnosis <10 minutes; first medical contact to balloon <90 minutes in a PCI centre; PCI within 120 minutes of diagnosis if transfer is needed.
  • Primary PCI is preferred (24×7 cath lab, experienced operators). If PCI is not possible within 120 minutes: fibrinolysis, then transfer; angiography at 3–24 hours if lysis succeeds, rescue PCI if it fails. In older people PCI is clearly better because lytics raise the risk of intracranial haemorrhage (TRIANA).
  • Drugs: DAPT (aspirin 75–100 mg + a P2Y12 inhibitor) with parenteral anticoagulation; avoid prasugrel at ≥75 years (more major and fatal bleeding); ticagrelor bleeds like clopidogrel. Early high-dose statin, beta-blocker, ACE inhibitor/ARB; a PPI on DAPT; adjust heparin for renal function.
  • Radial access in all ages cuts access-site bleeding; bleeding is poorly tolerated in older people and predicts death, reinfarction and stroke. Emergency CABG only for failed PCI or mechanical complications. ICD after VF, sustained VT or LVEF ≤30%.
  • Never withhold treatment on age alone — let CGA (frailty, cognition, life expectancy, preference) set the intensity. Offer cardiac rehabilitation routinely; it improves survival.
  • The 2025 ACC/AHA ACS guideline (one document for STEMI and NSTEMI): complete revascularisation is now Class 1, at the index procedure or staged (except in cardiogenic shock); ticagrelor or prasugrel preferred over clopidogrel after PCI; DAPT ≥12 months, then de-escalation to P2Y12 monotherapy is an option; a microaxial flow pump may be considered in selected shock.
  • The 2023 ESC guideline makes radial access the default; lipid lowering is now earlier and more aggressive (high-intensity statin ± ezetimibe).

Condensed by GeriClinics from the detailed answer below, with no new facts added.

15–20 High-Yield Points

DEFINITION AND DIAGNOSIS

1.

STEMI is an acute coronary syndrome caused by complete thrombotic occlusion of a coronary artery following plaque rupture or erosion — a Type 1 myocardial infarction.

2.

Diagnosis rests on three things: clinical presentation, ST-segment elevation on ECG, and a rise in high-sensitivity cardiac troponin.

3.

In older people the presentation is often atypical — dyspnoea, confusion, lethargy, epigastric pain, shoulder or back pain, or altered mental status rather than classic chest pain.

4.

Only a minority of older people with ischaemic heart disease complain of typical cardiac chest pain, so a high index of suspicion is essential.

PRINCIPLE OF REPERFUSION

5.

Total ischaemic time is the key concept — the greatest benefit from reperfusion occurs within the first 2–3 hours after symptom onset.

6.

Time targets: first medical contact to diagnosis <10 minutes; first medical contact to balloon (FMCTB) <90 minutes in a PCI centre; PCI within 120 minutes of diagnosis if transfer is needed.

7.

Primary PCI has replaced fibrinolysis as the preferred reperfusion strategy, provided it can be done immediately by experienced operators in a centre with 24×7 catheterisation laboratory activation.

8.

If PCI is not possible within 120 minutes, give fibrinolysis immediately, then transfer to a PCI centre. Perform coronary angiography at 3–24 hours if lysis succeeds, and rescue PCI if it fails.

9.

Older patients have an increased risk of intracranial haemorrhage with fibrinolytics, so PCI has clearly superior outcomes in this age group (TRIANA trial).

ADJUNCTIVE DRUG THERAPY

10.

Dual antiplatelet therapy (DAPT) — aspirin 75–100 mg daily plus a P2Y12 inhibitor — is given to all patients, along with parenteral anticoagulation.

11.

Prasugrel is not recommended in patients ≥75 years unless ischaemic risk is very high, because major and fatal bleeding are increased without added benefit.

12.

Ticagrelor can be used in older patients; its bleeding risk is similar to clopidogrel.

13.

Early high-dose statin therapy improves outcome. Beta blockers and ACE inhibitors/ARBs give prognostic benefit after ACS.

14.

Add a proton pump inhibitor in older patients on DAPT, especially with prior gastrointestinal bleeding.

15.

Unfractionated heparin dose must be adjusted for renal function in older people to reduce bleeding.

PROCEDURAL AND ELDERLY-SPECIFIC CONSIDERATIONS

16.

The trans-radial approach is now recommended in all age groups — it reduces access-site bleeding, which is the commonest non-cardiac complication of PCI.

17.

Bleeding is poorly tolerated in the elderly because of reduced LV function, vascular stiffness, and endothelial dysfunction; peri-procedural bleeding predicts death, reinfarction, and stroke.

18.

Emergency CABG is rarely needed — reserved for failed PCI or mechanical complications (papillary muscle rupture, ventricular septal rupture, free wall rupture).

19.

An implantable cardioverter-defibrillator (ICD) is advised after MI if there is ventricular fibrillation, sustained VT, or LVEF ≤30%.

20.

Treatment should never be withheld on the basis of age alone; instead use comprehensive geriatric assessment — frailty, cognition, life expectancy, and patient preference — to guide intensity of care.

21.

Cardiac rehabilitation improves survival in older coronary patients and should be offered routinely.

Current Practice Update

Textbook position (Pathy’s 6th ed.) Current evidence (2023–2026)

Primary PCI within 120 min; fibrinolysis if not available Unchanged and reinforced by the 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS guideline — the first major US update since 2013 Culprit-lesion PCI, with staged treatment of other vessels Complete revascularisation is now Class 1, and non-culprit PCI may be done at the index procedure or later (except in cardiogenic shock)

Clopidogrel, prasugrel, or ticagrelor as P2Y12 options Ticagrelor or prasugrel preferred over clopidogrel after PCI; prasugrel still avoided at ≥75 years DAPT duration guided by stent type Default DAPT ≥12 months if not high bleeding risk, then de-escalation to P2Y12 monotherapy is an accepted option Intra-aortic balloon pump for shock Microaxial flow pump may be considered in selected cardiogenic shock; prompt revascularisation remains Class 1 Latest Updates (2023–Present)

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guideline (Circulation 2025; JACC 2025) consolidates STEMI and NSTEMI into a single document and retires the 2013 STEMI and 2014 NSTE-ACS guidelines. Complete revascularisation for multivessel disease has been upgraded from Class 2a to Class 1, and can now be performed at the index procedure rather than only as a staged procedure (2025 ACC/AHA ACS Guideline). Potent P2Y12 inhibitors (ticagrelor or prasugrel) are explicitly preferred over clopidogrel in patients undergoing PCI, on the basis of superior reduction in major adverse cardiovascular events (2025 ACC/AHA ACS Guideline).

The 2023 ESC ACS Guideline (European Heart Journal 2023) similarly unified the ACS spectrum and recommends the radial approach as default and immediate invasive strategy for very-high-risk NSTE-ACS. Cardiogenic shock: prompt revascularisation remains Class 1; microaxial flow pump support may be considered in selected patients based on individual risk–benefit (2025 ACC/AHA ACS Guideline). Lipid management post-STEMI has become more aggressive, with early combination therapy (high-intensity statin ± ezetimibe) endorsed to reach LDL-C targets rapidly.

Examiner’s Tip — Mark-Earning Lines

“Total ischaemic time determines myocardial salvage; the greatest benefit is within the first 2–3 hours.” “FMCTB <90 minutes in a PCI centre; PCI within 120 minutes of diagnosis if transfer is required.” “Primary PCI is superior to fibrinolysis in the elderly, chiefly because of the higher risk of intracranial haemorrhage with lytics (TRIANA).”

“Prasugrel is avoided in patients ≥75 years because of excess major and fatal bleeding.” “Radial access reduces bleeding, and bleeding in the elderly independently predicts death, reinfarction, and stroke.” “The 2025 ACC/AHA ACS guideline made complete revascularisation Class 1 and preferred ticagrelor/prasugrel over clopidogrel.”

“Age alone is never a contraindication — use comprehensive geriatric assessment to individualise.”

How was your recall?

Rating marks the question complete. “Need another pass” also adds it to your bookmarks.

References

Spotted an error or something out of date?Report a problem with this page